利培酮治疗难治性分裂情感性精神病临床研究

目的：探讨利培酮用于治疗难治性分裂情感性精神病的临床疗效。方法84例分裂情感性精神病患者随机分为观察组与对照组，各42例，两组均予以碳酸锂治疗，观察组加用利培酮，对照组加用氯氮平，比较两组的临床疗效。结果两组治疗后HAMD、BRMS以及PANSS各项因子评分均降低，且观察组各因子评分低于对照组，差异具统计学意义（P＜0.05）；观察组的临床总有效率均高于对照组，差异具统计学意义（P＜0.05）；观察组的TESS评分显著低于对照组，差异具统计学意义（P＜0.05）。结论利培酮用于治疗难治性分裂情感性精神病疗效显著，不良反应少。

Clinical research on risperidone in the treatment of refractory schizoaffective psychosis

Objective To evaluate the clinical efficacy of risperidone for the treatment of refractory schizoaffective psychosis. Methods 84 patients with refractory schizoaffective psychosis were randomly divided into observation group and control group, and 42 cases were in each group.The two groups were received lithium treatment, and risperidone was added in observation group, while the control group added clozapine. The clinical efficacy of two groups were compared. Results After treatment, the HAMD, BRMS and the PANSS factor scores were significantly lower, but the observation group was significantly lower than the control group（P〈0.05）;the total effective rate of HAMD,BRMS and PANSS in observation group were significantly higher than the control group （P〈0.05）;the TESS score of observation group was significantly lower than the control group（P〈0.05）. Conclusion Risperidone for the treatment of refractory schizoaffective psychosis has a significant effect and less adverse reactions, it should be widely applied.